Defence Therapeutics Inc. has announced the significant expansion of its patent portfolio with several crucial issuances and allowances across multiple jurisdictions.
These developments solidify Defence’s position as a leader in innovative anti-cancer therapies and vaccine enhancement technologies.
Sébastien Plouffe, CEO and President of Defence, commented: “The recent issuance of these patents and allowances with broad claims covering our leading clinical candidates validates the innovative nature and the strength of our efficacy results, as we remain committed to the development of novel therapeutics for cancers.
“In addition, it secures Defence to negotiate licensing agreements with strong Biotech and Pharma companies.”
US patent allowance for Accum® multimers marks key milestone
In May 2023, Defence filed US patent application no. 18/318,384 (the ‘384 application) following its groundbreaking discovery that Accum®-based multimers exhibit superior stability and synergistic efficacy compared to monomeric forms.
The company also requested fast-track examination from the United States Patent and Trademark Office (USPTO).
On 17 October 2024, Defence received a Notice of Allowance from the USPTO, with the patent expected to be issued in early 2025 after the requisite fees are paid.
The patent includes valuable composition-of-matter claims covering Accum®-based dimers and multimers.
These molecular entities are integral to Defence’s AccuTOX® and ARM® anti-cancer programmes and can be utilised independently or conjugated with antigens, carriers, or antibodies.
Defence is actively exploring these conjugations for developing innovative antibody-drug conjugates (ADCs).
This US patent issuance will grant market exclusivity in the world’s largest commercial market for innovative cancer therapeutics, with protection extending to 2043.
Furthermore, the allowance validates the efficacy, innovation, and patentability of Defence’s Accum®-based dimer and multimer technology, a positive signal for the company’s planned international filings under PCT application no. PCT/CA2023/051758, scheduled for Q3 2025.
Expanded vaccine technology patents strengthen portfolio
Defence has also achieved new milestones in its vaccine technology platform, which utilises Accum® variants to enhance vaccine immunogenicity.
Building on its existing patents in the US, Canada, Australia, and Japan, Defence has now secured US patent no. 12,150,989 (the ‘989 patent), issued on 26 November 2024.
The ‘989 patent includes composition-of-matter claims covering Accum®-based immunogenicity-enhancing variants derived from any steroid acid. This addition significantly broadens the scope of Defence’s vaccine platform.
Further expanding its global reach, Defence announced the allowance of counterpart application no. 11202304388T by the Singaporean Patent Office.
The Singaporean patent is expected to be granted in early 2025, pending payment of government fees.
These achievements underscore Defence’s ongoing commitment to building a robust intellectual property foundation, enabling strategic partnerships to enhance the potency of both approved and developing vaccines.
Laying the groundwork for transformative growth
With the recent appointment of esteemed leaders, including Dr Svetlana Selivanova, Dr Maxime Parisotto, and Dr Elias Theodorou, Defence has positioned itself for a productive close to 2024 and a groundbreaking 2025.
The combination of strengthened intellectual property protections and strategic leadership enhances Defence’s ability to deliver on its mission: developing innovative therapies to improve patient outcomes worldwide.
As the company advances its clinical programmes and global patent strategy, it remains focused on bringing life-changing anti-cancer and vaccine technologies to market.
